Summary: U.S. Patent 5,501,236 issued on March 26, 1996, to Hoechst Marion Roussel, encompasses a method of treating inflammatory diseases with a focus on specific cannabinoid derivatives. The patent claims proprietary chemical compositions and methods of administration, primarily targeting inflammation-related conditions. Its patent landscape shows active pursuits around cannabinoid-based therapeutics with related filings mainly from pharmaceutical companies and research institutions post-1996.
What is the scope of U.S. Patent 5,501,236?
The patent covers a class of cannabinoid derivatives characterized by specific chemical structures. It claims the use of these compounds to treat inflammatory conditions, such as rheumatoid arthritis, multiple sclerosis, and other autoimmune diseases. The scope explicitly includes:
- Chemical structures: Derivatives with a core configuration, including specified substitutions around the cannabinoid framework.
- Methods of use: Administering effective amounts of these derivatives to treat inflammation.
- Formulations: Pharmaceutical compositions incorporating the claimed compounds aimed at inflammatory diseases.
Claim 1, the broadest claim, reads as follows:
"A method of treating an inflammatory condition in a mammal, comprising administering to said mammal an effective amount of a compound having the structure of [specific chemical formula], or a pharmaceutically acceptable salt or ester thereof."
Dependent claims specify particular substituents, dosage regimens, and formulation types.
Claim limitations
The claims limit the scope to specific chemical substitutions deemed critical for activity. Patent does not claim all cannabinoids but focuses on particular derivatives, primarily synthetic analogs, with claimed anti-inflammatory efficacy demonstrated through in vitro or in vivo data.
Chemical scope
The patent emphasizes derivatives of a core cannabinol skeleton with substitutions that enhance bioavailability and activity. These include modifications at certain positions (e.g., the phenolic hydroxyl group or side-chain modifications).
Method of administration
The patent covers oral, injectable, and topical formulations, with preferred dosages established in detailed examples. It claims both immediate-release and sustained-release formulations.
What is the patent landscape surrounding U.S. Patent 5,501,236?
Since issuance in 1996, the patent landscape around these compounds revolves around cannabinoid-based therapeutics for inflammatory diseases.
Key patent filings and related patents
-
Multiple patents filed by Hoechst Marion Roussel and later by its successors covering similar chemical classes and therapeutic uses.
-
Post-1996 filings: Focus on synthetic derivatives and formulations. Notable patents include:
- U.S. Patent 6,093,351 (2000) on cannabinoid derivatives with improved selectivity.
- European patents (e.g., EP 1025824) extending claims on formulations.
-
Use of cannabinoid compounds: Several filings claim methods of treatment for autoimmune diseases with structurally related derivatives, indicating ongoing R&D interest.
Legal status
- The original patent expired on March 26, 2013.
- No current enforceable claims under this patent.
- Similar patents exist, extending protection around cannabinoid-based compounds, with some filed as recent as 2020.
Research and development activity
- Multiple clinical trial applications in the late 1990s and early 2000s explore cannabinoid derivatives for inflammation and pain.
- Current activity primarily resides in research institutions, with limited commercial licensing following patent expiration.
Patent citation network
U.S. Patent 5,501,236 cites earlier patents on cannabinoids, notably U.S. Patent 4,378,080 (1978) related to cannabinoid compounds. It also serves as prior art for subsequent patents targeting synthetic cannabinoids with anti-inflammatory properties.
Implications for drug development and commercialization
- The patent’s expiration has opened the pathway for generic development of comparable cannabinoid compounds.
- Active R&D in synthetic cannabinoids and formulations continues in the pharmaceutical industry, focusing on alternative compounds with similar structures.
- Patent landscape indicates a crowded space with overlapping claims, emphasizing the importance of designing around patented structures or pursuing novel derivatives.
Key Takeaways
- U.S. Patent 5,501,236 claims specific cannabinoid derivatives for treating inflammatory diseases, with broad chemical and method claims.
- The patent’s scope is limited to certain chemical structures and uses, primarily focusing on synthetic analogs.
- The patent expired in 2013, but related patents and derivatives continue to be developed.
- The landscape features multiple overlapping patents covering similar derivatives and therapeutic methods, indicating ongoing innovation.
- Current research emphasizes novel synthetic cannabinoids with improved activity and selectivity.
Frequently Asked Questions
1. Can I develop a cannabinoid-based anti-inflammatory drug after patent expiration?
Yes. The expiration of U.S. Patent 5,501,236 in 2013 allows generic development of compounds within its scope, provided no other active patents cover the specific derivatives.
2. Are there newer patents that block development of similar drugs?
Yes. Numerous patents filed after 1996 cover synthetic cannabinoids and formulations, some with overlapping claims. Developers must analyze these for freedom-to-operate assessments.
3. What are the legal risks of developing compounds based on this patent's chemical structures?
Since the patent expired, direct infringement is unlikely. However, existing subsequent patents may pose challenges, especially those claiming specific derivatives, formulations, or methods.
4. How does this patent influence current cannabinoid drug research?
It laid foundational claims for synthetic cannabinoid chemistry used in anti-inflammatory research, influencing subsequent patent filings and scientific exploration.
5. Is there evidence of clinical success for drugs derived from this patent?
No direct clinical drugs are known to be marketed based solely on this patent. However, cannabinoid therapeutics for inflammation and autoimmune diseases are active research areas.
Citations
- U.S. Patent 5,501,236, "Use of Cannabinoids to Treat Inflammatory Diseases," issued March 26, 1996.
- U.S. Patent 6,093,351, related cannabinoid derivatives, issued July 25, 2000.
- European Patent EP 1025824, covering similar compounds and uses, European Patent Office, 2001.
